1-5 of 5
Catherine Dutreix
Close
Sort by
Journal Articles

A Phase 1/2, Open-Label, Dose-Escalation Study of Midostaurin in Pediatric Patients (Pts) with Relapsed or Refractory (R/R) Acute Leukemia: Final Results of Study ITCC-024 (CPKC412A2114)

C. Michel Zwaan, MD PhD, Stefan Söderhäll, MD PhD, Benoit Brethon, MD, Matteo Luciani, MD, Carmelo Rizzari, MD, David Sternberg, MD PhD, Emmanuelle Besse, Catherine Dutreix, MD, Franca Fagioli, MD, Phoenix Ho, MD, Carlo Dufour, MD, Rob Pieters, MD PhD
Journal: Blood
Blood (2015) 126 (23): 2564.
https://doi.org/10.1182/blood.V126.23.2564.2564
Published: 2015
Journal Articles

The Midostaurin (PKC412) Metabolite CGP52421 Shows Little Growth-Inhibitory Activity Against Against Neoplastic Mast Cells but Retains Inhibitory Effects on IgE-Dependent Activation and Histamine Release

Barbara Peter, D.V.M., Katharina Blatt, M.Sc., Gabriele Stefanzl, Emir Hadzijusufovic, DVM, Catherine Dutreix, Stefan H Gross, Johannes L Roesel, Peter Valent, M.D.
Journal: Blood
Blood (2011) 118 (21): 1417.
https://doi.org/10.1182/blood.V118.21.1417.1417
Published: 2011
Journal Articles

KIT Inhibitor Midostaurin Exhibits a High Rate of Clinically Meaningful and Durable Responses in Advanced Systemic Mastocytosis: Report of a Fully Accrued Phase II Trial

Jason Gotlib, Daniel J. DeAngelo, Tracy I. George, Christopher L. Corless, Andrea Linder, Cheryl Langford, Catherine Dutreix, Stefan Gross, Zariana Nikolova, Timothy Graubert
Journal: Blood
Blood (2010) 116 (21): 316.
https://doi.org/10.1182/blood.V116.21.316.316
Published: 2010
Journal Articles

A Phase I Study of Midostaurin (PKC412) Investigating Cardiac Interval Effects In Healthy Subjects

Adam del Corral, Catherine Dutreix, Alice Huntsman Labed, Sumita Rai, Kai Grosch, Joel Morganroth, Robert Harrell, Jr., Yanfeng Wang
Journal: Blood
Blood (2010) 116 (21): 4362.
https://doi.org/10.1182/blood.V116.21.4362.4362
Published: 2010
Journal Articles

A Phase 1b Study of Midostaurin (PKC412) in Combination with Daunorubicin and Cytarabine Induction and High-Dose Cytarabine Consolidation in Patients Under Age 61 with Newly Diagnosed De Novo Acute Myeloid Leukemia: Overall Survival of Patients Whose Blasts Have FLT3 Mutations Is Similar to Those with Wild-Type FLT3.

Richard M Stone, MD, Thomas Fischer, MD, Ronald Paquette, MD, Gary Schiller, MD, Charles A. Schiffer, MD, Gerhard Ehninger, MD, Jorge Cortes, MD, Hagop M. Kantarjian, MD, Daniel J. DeAngelo, MD, PhD, Alice Huntsman-Labed, Catherine Dutreix, MD, Sumita Rai, MD, Frank Giles, MD
Journal: Blood
Blood (2009) 114 (22): 634.
https://doi.org/10.1182/blood.V114.22.634.634
Published: 2009